Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.32.

EBIT: As of FY2026 Q1, the actual value is USD -1.304 M.

First Quarter 2026 Financial Results

Operating Expenses

• Research and Development Expenses: Pulmatrix, Inc.’s research and development expenses were $3 thousand for the three months ended March 31, 2026, compared to $19 thousand for the three months ended March 31, 2025. All clinical development is currently on hold as the Company works to license or monetize its clinical assets .
• General and Administrative Expenses: General and administrative expenses decreased by approximately $0.5 million to $1,289 thousand for the three months ended March 31, 2026, from $1,828 thousand for the three months ended March 31, 2025 . This decrease was primarily due to higher costs incurred in the prior year period related to the preparation and filing of a registration statement on Form S-4 .
• Total Operating Expenses: Total operating expenses were $1,292 thousand for the three months ended March 31, 2026, down from $1,847 thousand for the same period in 2025 .

Operating Profit / Loss

• Loss from Operations: The loss from operations was -$1,292 thousand for the three months ended March 31, 2026, compared to -$1,847 thousand for the three months ended March 31, 2025 .

Other Income (Expense)

• Interest Income: Interest income was $12 thousand for the three months ended March 31, 2026, compared to $53 thousand for the same period in 2025 .
• Fair Value Adjustment of Warrants: There was no fair value adjustment of warrants for the three months ended March 31, 2026, compared to $66 thousand for the same period in 2025 .
• Other Income (Expense), Net: Other income (expense), net, was $108 thousand for the three months ended March 31, 2026, compared to -$80 thousand for the same period in 2025 .
• Total Other Income (Expense), Net: Total other income (expense), net, was $120 thousand for the three months ended March 31, 2026, compared to $39 thousand for the same period in 2025 .

Net Loss

• Net Loss: The net loss for the three months ended March 31, 2026, was -$1,172 thousand, an improvement from a net loss of -$1,808 thousand for the three months ended March 31, 2025 .

Cash and Cash Equivalents

• Cash and Cash Equivalents Balance: As of March 31, 2026, Pulmatrix, Inc.’s total cash and cash equivalents balance was $3,324 thousand, down from $4,088 thousand as of December 31, 2025 .
• Current Restricted Cash: Current restricted cash was $700 thousand as of March 31, 2026, compared to $0 as of December 31, 2025 .
• Long-term Restricted Cash: Long-term restricted cash was $7 thousand as of March 31, 2026, compared to $10 thousand as of December 31, 2025 .

Assets

• Prepaid Expenses and Other Current Assets: Prepaid expenses and other current assets were $465 thousand as of March 31, 2026, compared to $41 thousand as of December 31, 2025 .
• Total Current Assets: Total current assets amounted to $4,489 thousand as of March 31, 2026, compared to $4,129 thousand as of December 31, 2025 .
• Total Assets: Total assets were $4,496 thousand as of March 31, 2026, compared to $4,139 thousand as of December 31, 2025 .

Liabilities

• Accounts Payable: Accounts payable increased to $651 thousand as of March 31, 2026, from $272 thousand as of December 31, 2025 .
• Accrued Expenses and Other Current Liabilities: Accrued expenses and other current liabilities were $254 thousand as of March 31, 2026, compared to $57 thousand as of December 31, 2025 .
• Total Current Liabilities: Total current liabilities were $905 thousand as of March 31, 2026, compared to $329 thousand as of December 31, 2025 .
• Total Liabilities: Total liabilities were $905 thousand as of March 31, 2026, compared to $329 thousand as of December 31, 2025 .

Stockholders’ Equity

• Total Stockholders’ Equity: Total stockholders’ equity was $3,591 thousand as of March 31, 2026, compared to $3,810 thousand as of December 31, 2025 .

Outlook / Guidance

Pulmatrix, Inc. anticipates its proposed merger with Eos SENOLYTIX to close in the third quarter of 2026, subject to customary closing conditions . The Company believes its current cash position is sufficient to fund operations at least through the anticipated closing of this merger .